Search AMCP NewsBreaks
On May 12, 2025, President Trump signed an Executive Order (EO) requiring agencies to take steps to encourage manufacturers to provide most-favored-nation pricing for prescription drugs.
On April 16, 2025, the Centers for Medicare and Medicaid Services (CMS) issued guidance on CY 2026 Part D Formulary Submissions (Guidance). The Guidance includes important dates related to CY 2026 formulary submissions.
On April 15, 2025, the Trump administration issued an Executive Order (EO) on prescription drug costs.
On April 7, 2025, the Centers for Medicare and Medicaid Services issued the Calendar Year (CY) 2026 Rate Announcement and Final CY 2026 Part D Redesign Program Instructions.
On April 4, 2025, the Centers for Medicare & Medicaid Services (CMS) released the Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (Part D Final Rule).
On March 27, 2025, the U.S. Department of Health and Human Services (HHS) issued a Fact Sheet: HHS’ Transformation to Make America Healthy Again. The document outlines HHS' restructuring plan as part of an initiative to enhance efficiency and address chronic diseases in America. Key changes include significant personnel reductions and consolidating divisions and offices to streamline operations.
On March 12, 2025, the Centers for Medicare & Medicaid Services (CMS) Innovation Center announced the early termination of several payment model trials by December 31, 2025.
On February 28, 2025, the Department of Health and Human Services (HHS) issued a Policy on Adhering to the Text of the Administrative Procedure Act (Policy Statement) rescinding a longstanding policy where HHS agencies used full “notice and comment” procedures beyond the minimum circumstances required by the Administrative Procedure Act (APA).
On February 21, 2025, the Centers for Medicare & Medicaid Services (CMS) announced public engagement events for the second cycle of the Medicare Drug Price Negotiation Program.
On February 20, 2025, the Department of Health and Human Services (HHS) Office for Civil Rights (OCR) rescinded prior guidance on gender-affirming care, entitled “HHS Notice and Guidance on Gender Affirming Care, Civil Rights, and Patient Privacy,” issued March 2, 2022 (2022 Guidance).
On January 17, 2025, the Centers for Medicare & Medicaid Services (CMS) issued the list of 15 additional Part D drugs for the Medicare Drug Price Negotiation Program.
In January 2025, the U.S. Department of Health and Human Services (HHS) issued a Strategic Plan for the Use of Artificial Intelligence in Health, Human Services, and Public Health in efforts to use AI responsibly to improve people's lives.
